12:00 AM
 | 
Apr 28, 2014
 |  BioCentury  |  Finance

Extra crisp

Why Versant Ventures thinks there's room for another CRISPR-Cas9 play
Extra crisp

Versant Ventures is adding another horse to the CRISPR-Cas9 therapeutics race with last week's $25 million series A round for CRISPR Therapeutics.

Versant was the sole investor in CRISPR, which is developing gene editing therapies for serious genetic diseases.

CRISPR (clustered, regularly interspaced short palindromic repeats)-Cas9 (CRISPR-associated protein 9) is a bacterial defense system that is guided by DNA-RNA base pairing and can induce site-specific mutations.

CEO Rodger Novak said the company is "in the process of...

Read the full 372 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >